91ÖÆƬ³§

Published on Market Research Reports® Inc. ()

Home > Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019

Publication ID: 
GMD1219105
Publication Date: 
December 16, 2019
Pages: 
1301
Publisher: 
Global Markets Direct
Countries: 
Global [1]
USD 2,000.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Drug Pipeline [2]
Pharma & Healthcare [3]
Description: 

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 5, 53, 65, 2, 6, 62, 7 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 9, 15 and 5 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents: 

Table of Contents
Introduction
Chronic Lymphocytic Leukemia (CLL) - Overview
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) - Drug Profiles
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
Appendix

List of Tables
List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Products under Development by Companies, H2 2019 (Contd..16), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Therapeutics Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acerta Pharma BV, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Adicet Bio Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AI Therapeutics, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor Bioscience LLC, H2 2019
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Anew Oncology Inc, H2 2019

List of Figures
List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

Companies Mentioned: 

4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
ABL Bio Inc
ACEA Therapeutics Inc
Acerta Pharma BV
ADC Therapeutics SA
Adicet Bio Inc
Adlai Nortye Biopharma Co Ltd
Aeglea BioTherapeutics Inc
AI Therapeutics
Altor Bioscience LLC
Anew Oncology Inc
Apotex Inc
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing GD Initiative Cell Therapy Technology Co Ltd
Beijing Immunochina Medical Science & Technology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
BendaRx Corp
Bio-Path Holdings Inc
BioIntegrator Ltd
Bionomics Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
CARsgen Therapeutics Ltd
CASI Pharmaceuticals Inc
Catapult Therapeutics BV
Celgene Corp
Cell Medica Ltd
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celltrion Inc
Cellular Biomedicine Group Inc
Celularity Inc
Centaurus Biopharma Co Ltd
CrystalGenomics Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Deciphera Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
Ergon Pharmaceuticals LLC
Eternity Bioscience Inc
Eureka Therapeutics Inc
Exinda Therapeutics LLC
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
GammaDelta Therapeutics Ltd
GeneaMed Ltd
Genentech Inc
Generium
Gilead Sciences Inc
GLG Pharma SA
Grid Therapeutics LLC
Grupo Ferrer Internacional SA
Guangzhou BeBetter Medicine Technology Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Heidelberg Pharma AG
Helocyte Biosciences Inc
Hengenix Biotech Inc
HRAIN Biotechnology Co Ltd
Hutchison MediPharma Ltd
Hybrigenics SA
iBio Inc
IGM Biosciences Inc
Immatics Biotechnologies GmbH
ImmuneTarget Inc
Immunomedics Inc
Incuron LLC
Incyte Corp
Inflection Biosciences Ltd
Innate Pharma SA
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Invectys SA
IO Biotech ApS
Iovance Biotherapeutics Inc
Johnson & Johnson
Juno Therapeutics Inc
Kancera AB
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
LegoChem Biosciences Inc
LFB SA
MEI Pharma Inc
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
MingSight Pharmaceuticals
Miragen Therapeutics Inc
MorphoSys AG
Mustang Bio Inc
Nanjing Sanhome Pharmaceutical Co Ltd
NantKwest Inc
NBE-Therapeutics AG
Neon Therapeutics Inc
Nichi-Iko Pharmaceutical Co Ltd
Nordic Nanovector ASA
NovalGen Ltd
Novartis AG
Nurix Inc
OncoTartis Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Panorama Research Inc
PEP-Therapy SAS
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Pharma Mar SA
Pharmapraxis
PIQUR Therapeutics AG
Plexxikon Inc
Precision Biosciences Inc
Promethera Biosciences SA
Qurient Co Ltd
Revitope Oncology Inc
Rhizen Pharmaceuticals SA
Sanofi
SFA Therapeutics LLC
Shanghai GeneChem Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Sian Wuhan Medical Technology Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
SpecificiT Pharma Inc
Supratek Pharma Inc
Surface Oncology Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TG Therapeutics Inc
Tolero Pharmaceuticals Inc
Trillium Therapeutics Inc
United BioPharma Inc
VelosBio Inc
Verastem Inc
Viralytics Pty Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
XEME BioPharma Inc

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ìý

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ìý

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/global-markets-direct/chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2019

Links
[1] /countries/global[2] /drug-pipeline[3] /pharma-healthcare